In fact, ZSTK474 effectively suppressed tumor cell growth at submicromolar concentrations, with the variance of GI50 concentrations across the 14 cell lines being small (within a 10-fold range) compared to the MEK inhibitor selumetinib (~1000-fold range). The gene discussed is MAP2K7; the disease is neoplasm.